
Debate Turns Raucous as House Panel Weighs Medicaid Cuts
'I know we have deep feelings on these issues, and we may not all agree on everything,' said Mr. Guthrie, a Republican who is in his first term as chairman of the House Energy and Commerce Committee.
It was not to be.
Minutes later, a group of protesters in the back of the Capitol Hill hearing room began shouting at lawmakers to 'keep your greedy hands off our Medicaid.'
They drowned out the chairman's calls for order, and Capitol Police officers ultimately removed five people — three in wheelchairs — as the dozens of lawmakers on the panel looked on. (The Capitol Police later said that officers had arrested 26 people for illegally protesting inside a congressional building.)
The disruptions were a raucous kickoff to a meeting that was expected to go all night and well into Wednesday — one committee member estimated it could take as long as 28 hours — as Republicans and Democrats sparred over the plan, a key part of major legislation to enact President Trump's domestic agenda.
It unfolded as the tax-writing House Ways and Means Committee met to consider a $2.5 trillion tax proposal that would extend Mr. Trump's 2017 tax cuts; temporarily fulfill his campaign pledges not to tax tips or overtime pay; roll back subsidies for clean energy; and create a new type of tax-advantaged investment account for children. A third panel, the House Agriculture Committee, was to meet Tuesday night to begin considering another piece of the bill that would slash nutrition assistance to help raise money for the plan.
But the bulk of the drama on Tuesday was at the Energy and Commerce Committee. During the first hour alone, Republicans giving opening statements were interrupted repeatedly by protesters who accused them of taking health care away from vulnerable people. G.O.P. lawmakers, in turn, accused Democrats of misrepresenting the Medicaid cuts they are proposing to score political points.
Mr. Guthrie labored to keep control over the proceedings, at one point presiding over a shouting match over whether members of his panel were allowed to use the word 'lying' in their remarks. (Republicans had been permitted to say that Democrats were lying about the scope of the Medicaid cuts, but Democrats were barred from saying that Mr. Trump was lying about his desire to protect the program. An informal agreement to simply avoid using the word 'lie' altogether for the remainder of the session fell apart a few hours later.)
Even some Democratic senators came to take in the spectacle. Senators Cory Booker of New Jersey, Brian Schatz of Hawaii and Tina Smith of Minnesota were on hand.
All before lawmakers had debated a single provision of the measure.
The bill's proposed reductions in Medicaid coverage and its expansion under the Affordable Care Act have become a flashpoint for Democrats and an area of concern for vulnerable Republicans who are wary of the political consequences of supporting cuts to insurance programs that have become popular with Americans.
Though House Republicans shied away from a huge structural overhaul of Medicaid, their proposal would reduce federal spending by an estimated $912 billion and cause 8.6 million people to become uninsured, according to a partial analysis from the Congressional Budget Office that was circulated by Democrats on the committee. Around $700 billion in cuts would come from changes to Medicaid and the Affordable Care Act.
Republicans argued that their proposed cuts would help control rising Medicaid costs by targeting 'waste, fraud and abuse' and ensuring the program's long-term health.
'Medicaid was created to protect health care for Americans who otherwise could not support themselves, but Democrats expanded the program far beyond this core mission,' Mr. Guthrie said.
Their proposal calls for stricter paperwork requirements across the program, makes changes that affect federal funding to states and adds a work requirement to Medicaid that requires poor, childless adults to prove they are working 80 hours every month to stay enrolled.
That provision, which targets an expansion of Medicaid under the Affordable Care Act, would not kick in until January 2029, after the next presidential election.
During their opening remarks, Democrats on the committee held up matching posters with photographs of constituents they deemed the 'faces of Medicaid.' The lawmakers told their stories as a way of humanizing people who rely on the program.
Representative Debbie Dingell of Michigan directly addressed a family who had traveled to Washington in the hearing, who she said needed Medicaid to care for a child with Down syndrome. Representative Marc Veasey of Texas held his phone up to the microphone, inviting a constituent to speak about how Medicaid affected her. Mr. Guthrie ruled that out of order.
Some of the people being highlighted were not at risk of losing coverage under the Republican proposal. And Democrats frequently claimed that the Republican plan would cause 13.7 million Americans to become uninsured, inflating the bill's effects on coverage by about five million people.
Pointing to these discrepancies, Republican lawmakers accused Democrats of dishonest politicking.
'Not a single person on these posters is going to be affected,' Representative Kat Cammack of Florida said.
'It's unfortunate that people are so enraged by misinformation,' Representative Gary Palmer, Republican of Alabama, said, referring to a woman who was taken from the room by the police after she shouted that she was H.I.V. positive and that the Medicaid cuts 'will kill me.'
The hallway outside the committee's hearing was packed with protesters, many of them wearing shirts or bearing signs that read 'Hands Off Medicaid.' Others wore shirts reading 'Fight for Planned Parenthood.' The organization is targeted by a provision in the bill that would block Medicaid from funding health providers that also offer abortion services.
'Hopefully, everyone understands that these demonstrations — people feel very strongly,' Representative Frank Pallone Jr., the top Democrat on the committee, said. 'Because they know they're losing their health care.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
CRISPR Therapeutics (CRSP) Sees 47% Price Increase Over Last Quarter
CRISPR Therapeutics recently announced significant developments in its in vivo cardiovascular disease programs, notably CTX310 and CTX320, which may have contributed to the company's 47% share price increase over the last quarter. The company's inclusion in multiple indices further enhances its market presence, potentially impacting investor interest positively. Meanwhile, CRISPR reported a net loss in its Q1 earnings, although revenue increased year-over-year. Despite a volatile market backdrop, characterized by declining major indices due to weak job reports and tariff concerns, CRISPR's advancements in therapeutic programs and strategic index additions contrasted against broader market movements. We've spotted 1 risk for CRISPR Therapeutics you should be aware of. Uncover the next big thing with financially sound penny stocks that balance risk and reward. Over the past year, CRISPR Therapeutics reported a total shareholder return of 9.74%. While the company's shares outperformed the US Biotechs industry, which returned a decline of 8.4% over the same period, it lagged behind the broader US Market's 17.7% return. The favorable performance relative to its industry can be linked to its strategic advancements in cardiovascular disease programs and inclusion in various Russell indices. The recent developments highlighted in the introduction, particularly the positive updates in CRISPR's cardiovascular programs and index additions, could potentially influence expectations around future revenue and earnings. Analysts forecast strong revenue growth of 57.3% annually, despite the company's forecast to remain unprofitable over the next three years. Meanwhile, with the current share price at $56.09, the market seems to discount the consensus analyst price target of $80.91, reflecting a substantial perceived upside potential in the stock. This price movement suggests that investors might see potential growth opportunities, even as the company navigates its profitability challenges. The valuation report we've compiled suggests that CRISPR Therapeutics' current price could be quite moderate. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CRSP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
17 minutes ago
- Yahoo
An Amazon seller doing 7 figures says one strategic addition has doubled her profit
Lisa Harrington started selling clothes on eBay before transitioning to Amazon. Her business selling interior cat doors took off after hiring a PPC coach. She emphasizes investing in coaching and networking for long-term business growth. Lisa Harrington's e-commerce career began in the early 2010s when she started selling clothing, purses, and other items in her closet that she didn't need anymore. She used the eBay profit to launch her first Amazon product — dog harnesses — and sold enough to quit her corporate job in 2016. She eventually created and patented interior cat doors, which have become a top-selling Amazon product and bring in seven figures in annual revenue. Harrington, who's been doing e-commerce for more than a decade, can pinpoint one decision that took her business to the next level: hiring a PPC coach. PPC (pay-per-click) refers to Amazon's advertising platform, where sellers can pay to have their products displayed prominently. Many sellers consider ads an essential aspect of succeeding in the competitive e-commerce space. For years, "I had a very low spend on my advertisement," Harrington told Business Insider. Figuring out how to run Amazon ads wasn't how she wanted to spend her time. "I just didn't have much interest in it. I really wanted to focus on branding and product development, but it has such an enormous impact on your profit and loss statement that you really can't ignore it." The idea to hire a coach came from an industry event. "I remember talking to this woman, and she's like, 'I hire a coach for everything I don't know how to do. It is the fastest way to level up,'" recalled Harrington. She took the advice, found a coach to help her specifically with ads, and, "in the time I've worked with her, my profit has doubled," said Harrington. It took her six months to find the right fit. "Coaches are hard to find. But when you do find one, it levels your business up," she said. Over the last couple of years, her PPC coach has become more of a general business coach. They discuss everything from product development to effective employee management. "She's the only person I can talk to about every aspect of my business. She not only has the expertise but has the background information, so I can spitball with her, solve problems, and come up with great ideas," said Harrington. The full-time entrepreneur and mother of two kids doesn't hesitate to outsource when she can. "I try to get a coach for everything because, thankfully, I've gotten to the point where I can pay people to help me," she said. "That, in some cases, tends to be a cheaper way to learn a skill or a cheaper way to get something done." Harrington is also a member of the elite group of seven-figure Amazon sellers called Million Dollar Sellers. Members must complete an interview and application and pay $7,497 a year to join the group, which grants them access to exclusive events and a robust network of top-tier entrepreneurs. She's adamant that investing in yourself "always pays dividends," she said. "The knowledge that you gain, the networks that you gain, the experience shares that you hear, the tips and tricks that you get access to — not only is that short-term helping your business and helping your profit and loss statement, but you're also learning all of those things, so that if everything fell apart tomorrow, you could rebuild it again." Read the original article on Business Insider Sign in to access your portfolio
Yahoo
17 minutes ago
- Yahoo
Cleveland-Cliffs (CLF) Reports Q2 2025 Sales Decline to US$4934 Million
Cleveland-Cliffs recently faced challenges as their second-quarter 2025 earnings revealed sales declined to USD 4,934 million, while registering a net loss of USD 483 million compared to a modest net income last year. Despite these disappointing financial results, Cleveland-Cliffs's share price rose by 15% over the past month. This performance unfolded against the backdrop of a broader market that saw similar gains in July, although markets experienced a downturn due to economic concerns fueled by weak U.S. jobs data and renewed tariff policies. The company's operational struggles might have tempered the overall positive market momentum. We've identified 3 risks with Cleveland-Cliffs (at least 1 which is a bit unpleasant) and understanding the impact should be part of your investment process. Find companies with promising cash flow potential yet trading below their fair value. The recent earnings report highlighting Cleveland-Cliffs' net loss of US$483 million amidst sales of US$4.93 billion presents a challenging landscape for the company. Despite this, shares have climbed 15% in the past month, reflecting broader market trends, though these gains might be vulnerable to ongoing economic uncertainties, such as the U.S. jobs data concerns. Addressing this financial strain is crucial as Cleveland-Cliffs navigates its reliance on U.S. steel tariffs and OEM reshoring, central to its growth narrative. Over a longer five-year period, Cleveland-Cliffs' total shareholder return, encompassing both share price appreciation and dividends, marked an impressive increase of 83.58%. This growth sharply contrasts with the company's recent underperformance against the US Metals and Mining industry over the past year. The industry saw returns of 13.4%, surpassing Cleveland-Cliffs' performance during the same one-year period. Future revenue and earnings projections are aligned with anticipated benefits from reshoring and tariff protections, yet the magnitude of the recent loss highlights potential vulnerabilities. Analysts anticipate the revenue will rise, with margins eventually reaching profitability. However, any shifts in trade policies or market conditions could alter these forecasts. With the current share price at US$10.06, close to the target of US$10.99, the upward movement suggests market confidence, yet analysts see limited upside relative to the target, indicating cautious optimism about hitting expected milestones. According our valuation report, there's an indication that Cleveland-Cliffs' share price might be on the cheaper side. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CLF. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data